Effects of the Total Saponins fromDioscorea nipponicaon Immunoregulation in Aplastic Anemia Mice

2015 ◽  
Vol 43 (02) ◽  
pp. 289-303 ◽  
Author(s):  
Yuliang Wang ◽  
Tiangai Yan ◽  
Lin Ma ◽  
Baoshan Liu
Keyword(s):  
Bone Marrow ◽  
Aplastic Anemia ◽  
Inflammatory Cytokine ◽  
Folk Medicine ◽  
Apoptosis Protein ◽  
Dioscorea Nipponica Makino ◽  
Regulation Mechanisms ◽  
Th1 Cytokines ◽  
Different Doses ◽  
Medium Dose

Dioscorea nipponica Makino, a popular folk medicine, exerts anti-inflammation properties. The present study investigated the therapeutic effect of the total saponins from Dioscorea nipponica Makino (TSDN) on aplastic anemia (AA) and possible immune regulation mechanisms. Using a mouse model of AA, three different doses of TSDN were orally administrated for 14 consecutive days. We first demonstrated that TSDN was found to be effective in alleviating pancytopenia with a hypocellular bone marrow as compared with AA model group. Moreover, gastrogavage administration of a medium dose of TSDN was found to dramatically increase the percentage of CD4+cells in bone marrow nucleated cells (BMNC) and restore the CD4+/CD8+ratio. The pro-inflammatory cytokine concentrations of IL-2 and IFN-γ were significantly decreased, and anti-inflammatory cytokine IL-4 was significantly increased in culture supernatant of BMNC. Further investigations showed that TSDN obviously inhibited Fas–FasL-induced BMNC apoptosis as well as effectively suppressed intracellular apoptosis protein of caspase-3 and -8 expressions. Taken together, these findings suggested that TSDN could alleviate AA by elevating the CD4+/CD8+T-cell ratio, inhibiting inflammatory Th1-cytokines, and exerting anti-apoptosis effects.

scholarly journals Albizia chinensis bark extract ameliorates the genotoxic effect of cyclophosphamide

2020 ◽  
Vol 44 (1) ◽  
Author(s):  
Marian Nabil ◽  
Entesar E. Hassan ◽  
Neven S. Ghaly ◽  
Fawzia A. Aly ◽  
Farouk R. Melek ◽  
...  
Keyword(s):  
Folk Medicine ◽  
Inhibitory Effect ◽  
Protective Role ◽  
Bark Extract ◽  
Repeated Treatment ◽  
Mouse Bone Marrow ◽  
Sperm Abnormalities ◽  
Wide Range ◽  
Different Doses

Abstract Background The genus Albizia (Leguminoseae) is used in folk medicine for the treatment of a wide range of ailments. Recently, saponins from plant origin have attracted much attention. Saponins are recorded to have a broad range of biological and pharmacological activities. This study was performed to evaluate the protective role of Albizia chinensis bark methanolic extract (MEAC) against the genotoxicity induced by cyclophosphamide (CP) using different mutagenic parameters. Results The results showed that MEAC induced an inhibitory effect against chromosomal aberrations of CP in mouse bone marrow and spermatocytes. Such effect was found to be significant (p < 0.01) with a dose of 100 mg/kg treated once for 24 h and also after repeated treatment at a dose of 25 mg/kg for 7 days. In sperm abnormalities, the protective effect of Albizia extract showed a dose-related relationship. Different doses of MEAC (25, 50, and 100 mg/kg) significantly (p < 0.01) ameliorated sperm abnormalities induced by CP dose-dependently. The percentage of sperm abnormalities was decreased to 5.14 ± 0.72 in the group of animals treated with CP plus MEAC (100 mg/kg) indicating an inhibitory effect of about 50%. Conclusion MEAC at the doses examined was non-genotoxic compared to control (negative) and exhibited a protective role against CP genotoxicity.

scholarly journals Hypoplastic Myelodysplastic Syndromes: Just an Overlap Syndrome?

Cancers ◽  
2021 ◽  
Vol 13 (1) ◽  
pp. 132
Author(s):  
Bruno Fattizzo ◽  
Fabio Serpenti ◽  
Wilma Barcellini ◽  
Chiara Caprioli
Keyword(s):  
Bone Marrow ◽  
Aplastic Anemia ◽  
Clonal Selection ◽  
Cytotoxic T Cells ◽  
Immunosuppressive Treatment ◽  
Young Patients ◽  
Suppressor Cells ◽  
Molecular Alterations ◽  
Molecular Features ◽  
Increased Risk

Myelodysplasias with hypocellular bone marrow (hMDS) represent about 10–15% of MDS and are defined by reduced bone marrow cellularity (i.e., <25% or an inappropriately reduced cellularity for their age in young patients). Their diagnosis is still an object of debate and has not been clearly established in the recent WHO classification. Clinical and morphological overlaps with both normo/hypercellular MDS and aplastic anemia include cytopenias, the presence of marrow hypocellularity and dysplasia, and cytogenetic and molecular alterations. Activation of the immune system against the hematopoietic precursors, typical of aplastic anemia, is reckoned even in hMDS and may account for the response to immunosuppressive treatment. Finally, the hMDS outcome seems more favorable than that of normo/hypercellular MDS patients. In this review, we analyze the available literature on hMDS, focusing on clinical, immunological, and molecular features. We show that hMDS pathogenesis and clinical presentation are peculiar, albeit in-between aplastic anemia (AA) and normo/hypercellular MDS. Two different hMDS phenotypes may be encountered: one featured by inflammation and immune activation, with increased cytotoxic T cells, increased T and B regulatory cells, and better response to immunosuppression; and the other, resembling MDS, where T and B regulatory/suppressor cells prevail, leading to genetic clonal selection and an increased risk of leukemic evolution. The identification of the prevailing hMDS phenotype might assist treatment choice, inform prognosis, and suggest personalized monitoring.

scholarly journals Treatment of aplastic anemia by bone marrow transplantation in identical twins

Blood ◽  
1980 ◽  
Vol 55 (6) ◽  
pp. 1033-1039 ◽  
Author(s):  
FR Appelbaum ◽  
A Fefer ◽  
MA Cheever ◽  
JE Sanders ◽  
JW Singer ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Aplastic Anemia ◽  
Marrow Transplantation ◽  
Identical Twins

REGRESSION OF OXYMETHOLONE-INDUCED HEPATIC TUMORS AFTER BONE MARROW TRANSPLANTATION IN APLASTIC ANEMIA

1980 ◽  
Vol 30 (2) ◽  
pp. 90-96 ◽  
Author(s):  
ROBERT R. MONTGOMERY ◽  
JONATHAN M. DUCORE ◽  
JOHN H. GITHENS ◽  
CHARLES S. AUGUST ◽  
MICHAEL L. JOHNSON
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Aplastic Anemia ◽  
Marrow Transplantation ◽  
Hepatic Tumors

Hepatitis-associated Aplastic Anemia Presenting as a Familial Bone Marrow Failure Syndrome

2009 ◽  
Vol 31 (11) ◽  
pp. 884-887 ◽  
Author(s):  
Vicky Rowena Breakey ◽  
Stephen Meyn ◽  
Vicky Ng ◽  
Christopher Allen ◽  
Inderjeet Dokal ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Aplastic Anemia ◽  
Bone Marrow Failure ◽  
Bone Marrow Failure Syndrome

Survival and quality of life in 23 patients with severe aplastic anemia treated with bone marrow transplantation (BMT)

1987 ◽  
Vol 54 (3) ◽  
pp. 137-146 ◽  
Author(s):  
W. Hinterberger ◽  
H. Gadner ◽  
P. H�cker ◽  
A. Hajek-Rosenmayr ◽  
W. Graninger ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Aplastic Anemia ◽  
Marrow Transplantation ◽  
Severe Aplastic Anemia

Anemia: Production Defects Generally Associated with Marrow Aplasia or Replacement

2017 ◽  
Author(s):  
Nancy Berliner ◽  
John M Gansner
Keyword(s):  
Bone Marrow ◽  
Differential Diagnosis ◽  
Aplastic Anemia ◽  
Blood Smear ◽  
Pure Red Cell Aplasia ◽  
Red Cell ◽  
Normal Bone Marrow ◽  
Normal Bone ◽  
Red Cell Aplasia

This review focuses on anemia resulting from production defects generally associated with marrow aplasia or replacement. The definition, epidemiology, etiology, pathogenesis, diagnosis, differential diagnosis, management, complications, and prognosis of the following production defects are discussed: Acquired aplastic anemia and acquired pure red cell aplasia. Figures depict a leukoerythroblastic blood smear, a biopsy comparing normal bone marrow and bone marrow showing almost complete aplasia, and a marrow smear. A table lists the causes of aplastic anemia. This review contains 3 figures; 1 table; 108 references.

Sign in / Sign up

Export Citation Format

Share Document